aiwiki.page
English
Health / Diseases & Symptoms / eosinophilia

Eosinophilia

Eosinophilia is an increased blood eosinophil count, commonly associated with allergic disease, parasitic infection, medication reactions, or certain blood disorders.

24 keywords1 linked from3 not yet writtenWritten by AI
EosinophilInflammationComplete Blood C…CorticosteroidBone MarrowFibrosisAsthmaAllergic Rhiniti…Eosinophil…

Eosinophilia is an increase in the number of circulating eosinophils, a type of white blood cell involved in immune responses and inflammation. It is generally defined as an absolute eosinophil count above 500500 cells per microliter of blood, although laboratory reference ranges vary. Eosinophilia is a laboratory finding rather than a single disease: its significance depends on its cause, persistence, and association with tissue or organ injury.

Definition and measurement

Eosinophils are measured as part of a complete blood count with a white blood cell differential. The absolute eosinophil count, rather than the percentage of eosinophils alone, is the principal measure used to define eosinophilia:

Absolute eosinophil count=total white blood cell count×eosinophil percentage100.\text{Absolute eosinophil count} = \text{total white blood cell count} \times \frac{\text{eosinophil percentage}}{100}.

A high eosinophil percentage does not necessarily indicate an increased absolute count if the total white blood cell count is low. Conversely, a normal percentage can coexist with an increased absolute count when the total white blood cell count is high.

A commonly used classification is:

Degree Absolute eosinophil count
Mild 500500 to less than 1,5001{,}500 cells/µL
Moderate 1,5001{,}500 to 5,0005{,}000 cells/µL
Severe More than 5,0005{,}000 cells/µL

An absolute count of at least 1,5001{,}500 cells/µL is commonly termed hypereosinophilia, particularly when confirmed on repeated measurements. Blood counts fluctuate, and medications such as corticosteroids can suppress them.

Blood eosinophilia and tissue eosinophilia are related but distinct findings. Eosinophils may accumulate in an organ without a substantial increase in the blood, and marked blood eosinophilia does not invariably produce organ damage.

Biological basis

Eosinophils develop in the bone marrow and circulate briefly before entering tissues. Their production, survival, and activation are influenced by immune signaling molecules, particularly interleukin-5. They participate in responses to some parasites and in allergic and other inflammatory processes.

Activated eosinophils release granule proteins, inflammatory mediators, and enzymes. These substances can contribute to tissue injury, abnormal clot formation, and fibrosis. The circulating count alone is therefore an incomplete measure of disease activity: tissue distribution, cellular activation, and the underlying disorder also matter.

Causes

Reactive eosinophilia

Reactive, or secondary, eosinophilia occurs when another condition stimulates eosinophil production or survival. Major causes include:

  • Allergic and atopic disorders. Asthma, allergic rhinitis, and eczema commonly produce mild eosinophilia. An allergic diagnosis does not, by itself, explain every persistent or markedly elevated count.
  • Parasitic infections. Certain helminth infections, especially those involving migration through tissues, can cause substantial eosinophilia. Not all parasites cause it, and many intestinal protozoal infections do not.
  • Medication reactions. Medicines can cause isolated eosinophilia or systemic hypersensitivity reactions involving rash, fever, and internal-organ injury. The count alone does not establish that a medicine is responsible.
  • Inflammatory and immune-mediated disorders. These include eosinophilic granulomatosis with polyangiitis, a form of vasculitis, and some other inflammatory diseases.
  • Malignancy-associated immune responses. Some cancers, including Hodgkin lymphoma and certain other lymphomas, can stimulate eosinophilia through signaling molecules produced by tumor cells or surrounding immune cells.
  • Endocrine disorders. Adrenal insufficiency can be associated with eosinophilia.

The relative frequency of these causes varies with geography, medication exposure, and the population being examined.

Clonal and lymphocyte-driven eosinophilia

In clonal eosinophilia, eosinophils arise from an abnormal blood-forming cell population. This can occur in particular forms of leukemia and other myeloid neoplasms. Some disorders have characteristic genetic rearrangements involving genes such as PDGFRA, PDGFRB, or FGFR1. Identifying these abnormalities can affect disease classification and treatment selection.

A different mechanism occurs when an abnormal T-cell population produces signals that stimulate otherwise reactive eosinophils. This is recognized in the lymphocytic variant of hypereosinophilic syndrome.

Organ-restricted eosinophilic disorders

Eosinophilic inflammation can predominantly affect one organ system, as in eosinophilic esophagitis, eosinophilic gastrointestinal disease, and eosinophilic pneumonia. Peripheral blood eosinophilia may be present or absent. These disorders require organ-specific diagnostic criteria rather than a blood count alone.

Hypereosinophilic syndrome

Hypereosinophilic syndrome refers to hypereosinophilia accompanied by organ damage or dysfunction attributable to eosinophils. It is not synonymous with an elevated eosinophil count.

Historical definitions required eosinophilia to persist for six months. Contemporary definitions do not require that waiting period when eosinophil-related organ injury is evident. Classification distinguishes reactive, neoplastic, and idiopathic forms; idiopathic indicates that no underlying cause has been established after evaluation.

Potential manifestations include skin disease, lung involvement, gastrointestinal symptoms, peripheral nerve injury, cardiac inflammation, and thrombosis. Cardiac involvement may progress to scarring and heart failure. Some people have persistent hypereosinophilia without identifiable organ injury and therefore do not meet criteria for the syndrome.

Clinical evaluation

The diagnostic assessment addresses both the cause of eosinophilia and the presence of organ involvement. Its scope depends on the degree and duration of the elevation and associated findings.

Relevant information includes previous blood counts, medication and supplement exposure, allergic disease, travel or residence in areas with parasitic infections, and systemic symptoms. A physical examination may identify skin changes, enlarged lymph nodes, or enlargement of the liver or spleen.

Investigations may include repeat blood counts, examination of a peripheral blood smear, organ-function tests, and infection testing selected according to exposure history. Stool testing alone does not reliably exclude every helminth infection. Evaluation for strongyloidiasis is particularly relevant in exposed individuals because corticosteroid treatment can precipitate severe infection.

Persistent unexplained hypereosinophilia, abnormal blood-cell morphology, or other features suggesting a blood disorder may lead to bone marrow examination and molecular testing. Imaging, cardiac testing, and biopsy are used selectively to investigate suspected tissue injury.

Treatment and clinical course

Treatment is directed at the underlying disorder and any eosinophil-mediated organ damage, rather than at a blood count in isolation. Depending on the diagnosis, clinical management may involve treatment of a parasitic infection, withdrawal of an implicated medicine, control of inflammatory disease, or therapy for a blood malignancy.

Corticosteroids reduce eosinophil numbers and activity in many inflammatory conditions. Certain genetically defined neoplasms respond to targeted kinase inhibitors, while selected eosinophilic disorders can be treated with monoclonal antibodies directed against interleukin-5 or its receptor.

The clinical course ranges from transient, asymptomatic elevations to persistent disease with serious organ complications. Changes in the blood count are interpreted alongside symptoms and organ findings because a lower count does not necessarily indicate resolution of established tissue damage.